CoChat

Safety of Lactobacillus Strains as Probiotic Agents

Reid, Gregor · 2002 · Clinical Infectious Diseases
Cited by 36

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

SIR—Although I agree with Sipsas et al. [1] that any report of organisms causing disease needs to be taken seriously, I disagree with many of the points they make in their letter. First of all, the original review that they cite [2], although laudable, included several important inaccuracies, starting with a definition for probiotics that the authors of the review appear to have made up. Probiotics should be defined as “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [3, p. 2]. The original review [2] wrongly stated that probiotic products used in Europe differ from those used in the United States, because, for example, Lactobacillus rhamnosus GG is used on both continents. Furthermore, the authors of that review [2] and Sipsas et al. [1] missed a critical point: for a strain of Lactobacillus to be considered a probiotic, it first must have been shown to confer health benefits on the host [3]. Unfortunately, countless numbers of “probiotic” products on the market—and too many organisms cited in the literature as “probiotics”—have never been shown to confer any health benefits on the host. At best, there are a handful of strains for which there is evidence of an associated health benefit [4]. Yet, even with so many pseudoprobiotic products available, which often have unreliable contents [5], very few case reports of side effects have been reported [6]. The case report [7] cited by Sipsas et al. [1] lacks essential details necessary for useful conclusions to be made. The patient consumed “heavy daily” amounts of undisclosed dairy products that may or may not have contained a probiotic strain (probably they did not, given that few such strains are available). There is no mention of the patient being immunocompromised, as stated by Sipsas et al. [1]. The patient had constipation, but we do not know whether it resolved because the patient ate dairy products or whether it was caused by excessive eating. Did the patient sustain a microscopic intestinal lesion as a result of the constipation or colonoscopy? Did the laxative preparation given before colonoscopy include an antibiotic? Either way, the intestinal flora was disrupted. Because the isolates did not undergo molecular identification, and because no attempt was made to determine whether they were the same as the strains in the yogurt ingested by the patient, it is a stretch to say there is any evidence of a correlation between the endocarditis and the patient's diet, never mind the ingestion of a true probiotic. It is difficult to determine how many people use probiotics safely on a daily basis. The manufacturer of the product Yakult, which contains Lactobacillus casei strain Shirota, claims sales of >9 billion bottles per year. Sales by Danone, Valio, and other manufacturers of products that contain probiotics for which there is evidence of health benefit likely increase that figure to >20 billion doses per year. To raise fears of endocarditis on the basis of 4 cases (yogurt is not a probiotic, so I have discounted 6 of the cases mentioned by Sipsas et al. [1]) that have occurred in 10 years, after perhaps 200 billion doses of probiotic products have been ingested around the globe, is to exaggerate and misrepresent the true risks of probiotic therapy. With respect to safety, credible scientists in the field of probiotics have long cautioned that use of any therapy, including administration of lactobacilli, foods, or pharmaceuticals, should take into account the condition of the patient or end user. For some immunocompromised patients and patients with intestinal bleeding, probiotic ingestion may or may not have beneficial results. Because probiotic products are readily available over the counter, there is an onus on the consumer to understand what they are buying. Sipsas and colleagues, citing a 2001 study [8] in which the infecting organism could not be correlated with that isolated from yogurt ingested by the patient, have failed to show an “increasing number of reports that suggest a pathogenic role for the lactobacilli used as probiotic agents” [1, p. 1284]. Rather, they have raised false alarms on the basis of personal perceptions. If they describe pathogenic virulence factors produced by well-proven probiotic organisms in highly reliable product formulations and then show that these are expressed in patients with disease, then we will gladly take notice. Until then, there is good evidence that properly tested probiotics have an enormous potential to prevent disease and, in some cases, treat it. Until this message is taken seriously by health care professionals, governments, and industry, rumormongering is not constructive. Pick up any pharmaceutical compendium and you will find many reasons why we should be more concerned with the side effects of drugs than with the safety of probiotics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/342477

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 36

Metadata

Authors
Reid, G.
Venue
Clinical Infectious Diseases
Published
2002-08
Volume
35
Issue
3
Pages
349-350
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2165350915
Cited by
36
References
1
FWCI
6.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Lactobacillus Strains as Probiotic Agents. https://app.cochat.ai/papers/10.1086/342477
The paper
Reid, G. (2002). Safety of Lactobacillus Strains as Probiotic Agents. Clinical Infectious Diseases. https://doi.org/10.1086/342477

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.